MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Adaptimmune Therapeutics PLC - Company Profile (NASDAQ:ADAP)

Consensus Ratings for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) (?)
Ratings Breakdown: 1 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $18.57 (88.54% upside)

Analysts' Ratings History for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)
Show:
DateFirmActionRatingPrice TargetActions
4/24/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2016Deutsche BankInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2015SunTrustInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015GuggenheimInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Bank of AmericaInitiated CoverageNeutral$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/27/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha